Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
CG Oncology has the lowest figure of the 24 biotech ranked by total liabilities, at CZK 867M, followed by Immunovant (CZK 2.3B) and Krystal Biotech (CZK 2.5B). Figures as of 18 Nov 2026, 15:56 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- Lowest
- CG OncologyCZK 867M
- Median
- CZK 15.6B
- Combined market value
- CZK 18.69T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | CG OncologyCGON · Health Care | CZK 867M | CZK 159B | CZK 1,780.06 | 1.41% up | 85% up | ||
| 2 | ImmunovantIMVT · Health Care | CZK 2.3B | CZK 154.8B | CZK 748.12 | 1.31% up | 43% up | ||
| 3 | Krystal BiotechKRYS · Health Care | CZK 2.5B | CZK 203.4B | CZK 6,864.30 | 3.40% up | 46% up | ||
| 4 | Scholar Rock HoldingSRRK · Health Care | CZK 3.5B | CZK 127.9B | CZK 1,048.20 | 4.57% up | 14% up | ||
| 5 | Kymera TherapeuticsKYMR · Health Care | CZK 3.6B | CZK 228.2B | CZK 2,673.19 | 1.07% down | 87% up | ||
| 6 | Twist BioscienceTWST · Health Care | CZK 3.8B | CZK 175.3B | CZK 2,571.13 | 3.24% up | 340% up | ||
| 7 | Kodiak SciencesKOD · Health Care | CZK 4.3B | CZK 141.4B | CZK 2,162.43 | 0.46% up | 396% up | ||
| 8 | Adaptive BiotechnologiesADPT · Health Care | CZK 6.4B | CZK 103.4B | CZK 638.83 | 0.84% up | 88% up | ||
| 9 | VaxcytePCVX · Health Care | CZK 7.1B | CZK 205.1B | CZK 1,295.68 | 1.90% down | 22% up | ||
| 10 | CRISPR TherapeuticsCRSP · Health Care | CZK 7.6B | CZK 89.9B | CZK 926.57 | 3.79% up | 21% down | ||
| 11 | Bio-TechneTECH · Health Care | CZK 10.6B | CZK 254.1B | CZK 1,617.43 | 0.15% up | 26% up | ||
| 12 | ExelixisEXEL · Health Care | CZK 15.2B | CZK 373.6B | CZK 1,531.16 | 0.53% up | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | CZK 16.1B | CZK 771.7B | CZK 3,567.96 | 1.37% down | 131% up | ||
| 14 | RepligenRGEN · Health Care | CZK 18.8B | CZK 244.5B | CZK 3,825.45 | 6.08% up | 5% up | ||
| 15 | ImmunityBioIBRX · Health Care | CZK 22.3B | CZK 156.6B | CZK 147.20 | 5.75% up | 193% up | ||
| 16 | argenxARGX · Health Care | CZK 30.2B | CZK 1.33T | CZK 21,085.99 | 0.08% up | 4% up | ||
| 17 | Neurocrine BiosciencesNBIX · Health Care | CZK 30.6B | CZK 366.7B | CZK 3,622.79 | 1.80% down | 20% up | ||
| 18 | Halozyme TherapeuticsHALO · Health Care | CZK 55.1B | CZK 246.7B | CZK 2,163.99 | 1.41% up | 37% up | ||
| 19 | QiagenQGEN · Health Care | CZK 55.7B | CZK 227.9B | CZK 1,103.45 | 0.25% down | 12% up | ||
| 20 | BioNTechBNTX · Health Care | CZK 68.2B | CZK 463.6B | CZK 1,869.81 | 0.91% down | 16% down | ||
| 21 | ModernaMRNA · Health Care | CZK 82B | CZK 1.82T | CZK 4,502.75 | 2.08% down | 755% up | ||
| 22 | BiogenBIIB · Health Care | CZK 248.7B | CZK 821.3B | CZK 5,556.06 | 0.37% down | 49% up | ||
| 23 | Gilead SciencesGILD · Health Care | CZK 809.5B | CZK 4.65T | CZK 3,748.07 | 1.00% down | 33% up | ||
| 24 | AmgenAMGN · Health Care | CZK 1.82T | CZK 5.38T | CZK 9,945.41 | 2.33% down | 34% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2358 CZK).
Questions and answers
Which biotech have the lowest total liabilities?
CG Oncology (CZK 867M), Immunovant (CZK 2.3B) and Krystal Biotech (CZK 2.5B) have the lowest total liabilities of the 24 biotech ranked here as of 18 Nov 2026, 15:56 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of CZK 18.69T as of 18 Nov 2026, 15:56 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.